The Beauty Health Company
NASDAQ:SKINHousehold & Personal Products
+$0.04 today
- Market cap
- $81.18M
- Beta
- 1.07
- P/E (TTM)
- -14.6
- EPS (TTM)
- -$0.05
Volume 0.05M
Average 0.95M
SKIN Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
The Beauty Health CompanyNASDAQ: SKIN
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue declines year over year
Q1 FY2026 revenue of $64.9M fell 6.7% year over year, ahead of the -8.2% change in trailing-twelve-month revenue. Sequentially, it fell 21.2% from the prior quarter. Over 3 fiscal years it compounded at -6.3% a year.
Context
- Revenue increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 7 analysts of $285.39M (-5.1%) for the fiscal year ending Dec 2026, a step up from the -10.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $64.9M-21.2% QoQ
- Last fiscal yearDec 2025
- $300.79M-10.0% YoY
- LTMMar 2026
- $296.11M-8.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -6.7% | -4.8% | +1.9 pp |
| 1 year | -10.0% | -5.1% | +4.9 pp |
| 3-year CAGR | -6.3% | +0.0% | +6.3 pp |
| 5-year CAGR | +1.7% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 300.79M USD
- Year-over-year change
- -10.0%
- 4-year CAGR
- +3.7%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 300.79M | -10.0% |
| FY2024 | 2024-12-31 | 334.29M | -16.0% |
| FY2023 | 2023-12-31 | 397.99M | +8.8% |
| FY2022 | 2022-12-31 | 365.88M | +40.7% |
| FY2021 | 2021-12-31 | 260.09M | — |
Revenue vs competitors
How SKIN compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of -8.2% is the 6th highest of 7, against a peer median of +7.8%.
- Over three fiscal years its annual growth of -6.3% compares with a peer median of +9.5%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| FY2025 | CN¥1.85B CNY | +16.9% | +36.8% | |
| LTM Apr 2026 | $482.97M USD | -8.4% | -2.6% | |
| LTM Mar 2026 | $296.11M USD | -8.2% | -6.3% | |
| LTM Mar 2026 | $202.88M USD | +3.8% | +0.4% | |
| LTM Mar 2026 | $169.33M USD | +9.8% | -0.4% | |
| LTM Mar 2026 | $90.85M USD | +42.3% | +41.4% | |
SLSNSolesence, Inc. Common Stock | LTM Mar 2026 | $60.4M USD | +5.8% | +18.5% |
| Peer median (excluding SKIN) | — | +7.8% | +9.5% | |
Competitors are the stored peer set for SKIN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 260.09M | 365.88M | 397.99M | 334.29M | 300.79M |
| Cost of Revenue | 81.55M | 117.1M | 242.88M | 152M | 104.43M |
| Gross Profit | 178.54M | 248.78M | 155.11M | 182.3M | 196.36M |
| Gross Margin | 68.6% | 68.0% | 39.0% | 54.5% | 65.3% |
| Research & Development | 8.2M | 8.44M | 10.1M | 6.3M | 5.63M |
| Selling, General & Admin | 210.27M | 266.18M | 275.93M | 243.77M | 211.54M |
| Operating Expenses | 218.47M | 274.62M | 286.03M | 250.07M | 217.17M |
| Depreciation & Amortization | 17.93M | 22.87M | 34.68M | 29.48M | 25.35M |
| EBITDA | (350.93M) | 81.6M | (53.57M) | 10.34M | 38.74M |
| EBITDA Margin | -134.9% | 22.3% | -13.5% | 3.1% | 12.9% |
| Operating Income | (39.93M) | (25.84M) | (130.92M) | (67.77M) | (20.8M) |
| Operating Margin | -15.4% | -7.1% | -32.9% | -20.3% | -6.9% |
| Interest Income | 39K | 9.18M | 23.17M | 16.64M | 8.95M |
| Interest Expense | 11.78M | 13.39M | 13.65M | 10.41M | 19.33M |
| Other Income / Expenses | (340.71M) | 71.18M | 29.03M | 38.22M | 14.87M |
| Income Before Tax | (380.64M) | 45.34M | (101.89M) | (29.55M) | (5.94M) |
| Pre-Tax Margin | -146.4% | 12.4% | -25.6% | -8.8% | -2.0% |
| Income Tax Expense | (1.88M) | 1.12M | (1.77M) | (452K) | 3.58M |
| Net Income | (378.76M) | 44.22M | (100.12M) | (29.1M) | (9.52M) |
| Net Margin | -145.6% | 12.1% | -25.2% | -8.7% | -3.2% |
| EPS (Basic) | (3.67) | 0.30 | (0.76) | (0.23) | (0.08) |
| EPS (Diluted) | (3.67) | (0.23) | (0.76) | (0.36) | (0.16) |
| Weighted Avg Shares | 102.11M | 147.55M | 131.68M | 123.83M | 126.38M |
| Weighted Avg Shares (Diluted) | 102.11M | 148.51M | 131.68M | 142.49M | 135.8M |
The Beauty Health Company
NASDAQ:SKIN
Intrinsic Alpha fair value
Locked
Current Price
$12.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.